Literature DB >> 19942084

Inflammation in atherosclerosis: from pathophysiology to practice.

Peter Libby1, Paul M Ridker, Göran K Hansson.   

Abstract

Until recently, most envisaged atherosclerosis as a bland arterial collection of cholesterol, complicated by smooth muscle cell accumulation. According to that concept, endothelial denuding injury led to platelet aggregation and release of platelet factors which would trigger the proliferation of smooth muscle cells in the arterial intima. These cells would then elaborate an extracellular matrix that would entrap lipoproteins, forming the nidus of the atherosclerotic plaque. Beyond the vascular smooth muscle cells long recognized in atherosclerotic lesions, subsequent investigations identified immune cells and mediators at work in atheromata, implicating inflammation in this disease. Multiple independent pathways of evidence now pinpoint inflammation as a key regulatory process that links multiple risk factors for atherosclerosis and its complications with altered arterial biology. Knowledge has burgeoned regarding the operation of both innate and adaptive arms of immunity in atherogenesis, their interplay, and the balance of stimulatory and inhibitory pathways that regulate their participation in atheroma formation and complication. This revolution in our thinking about the pathophysiology of atherosclerosis has now begun to provide clinical insight and practical tools that may aid patient management. This review provides an update of the role of inflammation in atherogenesis and highlights how translation of these advances in basic science promises to change clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942084      PMCID: PMC2834169          DOI: 10.1016/j.jacc.2009.09.009

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  66 in total

1.  Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas.

Authors:  Koichi Shimizu; Masayoshi Shichiri; Peter Libby; Richard T Lee; Richard N Mitchell
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

2.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

3.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

Review 4.  Chemokines and their receptors: drug targets in immunity and inflammation.

Authors:  Antonella Viola; Andrew D Luster
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.

Authors:  Robert J Glynn; Jean G MacFadyen; Paul M Ridker
Journal:  Clin Chem       Date:  2008-12-18       Impact factor: 8.327

6.  Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?

Authors:  S Matthijs Boekholdt; Robbert J de Winter; John J P Kastelein
Journal:  Circulation       Date:  2008-09-09       Impact factor: 29.690

Review 7.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

Review 8.  Intertwining of thrombosis and inflammation in atherosclerosis.

Authors:  Kevin Croce; Peter Libby
Journal:  Curr Opin Hematol       Date:  2007-01       Impact factor: 3.284

9.  The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography.

Authors:  Nobuhiro Tahara; Hisashi Kai; Hiroyuki Nakaura; Minori Mizoguchi; Masatoshi Ishibashi; Hayato Kaida; Kenkichi Baba; Naofumi Hayabuchi; Tsutomu Imaizumi
Journal:  Eur Heart J       Date:  2007-08-05       Impact factor: 29.983

10.  Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.

Authors:  David A Morrow; Yunmei Wang; Kevin Croce; Masashi Sakuma; Marc S Sabatine; Huiyun Gao; Aruna D Pradhan; Aileen M Healy; Jacki Buros; Carolyn H McCabe; Peter Libby; Christopher P Cannon; Eugene Braunwald; Daniel I Simon
Journal:  Am Heart J       Date:  2007-11-01       Impact factor: 4.749

View more
  637 in total

1.  Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6.

Authors:  Vanessa Cavieres; Karla Valdes; Brayan Moreno; Rodrigo Moore-Carrasco; Daniel R Gonzalez
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

2.  Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Phoebe A Stapleton; Stephanie J Frisbee; Alexandre C d'Audiffret
Journal:  Physiol Genomics       Date:  2010-06-08       Impact factor: 3.107

Review 3.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

Review 4.  The evolution of endothelial regulatory paradigms in cancer biology and vascular repair.

Authors:  Joseph W Franses; Elazer R Edelman
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

5.  Evaluation of early atherosclerosis in patients with inflammatory bowel disease.

Authors:  Hasan Kayahan; Ismail Sari; Nesat Cullu; Fahize Yuksel; Serdal Demir; Mesut Akarsu; Yigit Goktay; Belkis Unsal; Hale Akpinar
Journal:  Dig Dis Sci       Date:  2012-04-01       Impact factor: 3.199

6.  Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis.

Authors:  Sean D Allen; Yu-Gang Liu; Taehyeung Kim; Sharan Bobbala; Sijia Yi; Xiaohan Zhang; Jaehyuk Choi; Evan A Scott
Journal:  Biomater Sci       Date:  2019-01-29       Impact factor: 6.843

7.  Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss.

Authors:  Huaiping Yuan; Sami Zelkha; Sami Zelka; Marina Burkatovskaya; Rohit Gupte; Susan E Leeman; Salomon Amar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

8.  Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6.

Authors:  Chantelle M Rein-Smith; Nathan W Anderson; David H Farrell
Journal:  Thromb Res       Date:  2012-10-01       Impact factor: 3.944

9.  Shiftwork and Biomarkers of Subclinical Cardiovascular Disease: The BCOPS Study.

Authors:  Meghan M Holst; Michael D Wirth; Anna Mnatsakanova; James B Burch; Luenda E Charles; Cathy Tinney-Zara; Desta Fekedulegn; Michael E Andrew; Tara A Hartley; John M Violanti
Journal:  J Occup Environ Med       Date:  2019-05       Impact factor: 2.162

Review 10.  Screening low-risk individuals for coronary artery disease.

Authors:  Chintan S Desai; Roger S Blumenthal; Philip Greenland
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.